Protein-bound Versus Free Amino Acid Nutrition During INtestinal Malabsorption in Critical Illness

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

16 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-03-27

Study Completion Date

2019-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In the current study, we willquantitate the difference in digestion and absorption kinetics of dietary whole protein versus free amino acids in vivo in critically ill patients admitted to the intensive care unit suffering from malabsorption. 16 adult, mechanically ventilated ICU patients with clinical signs of malabsorption (faecal weight \>350 g/day) will be included. All patients will receive a primed continuous intravenous infusion of L-\[ring2H5\]-phenylalanine and L-\[3,5-2H2\]-Tyrosine for the duration of the study period. After reaching an isotopic steady state (1.5 hours), patients will receive either \[1-13C\]- phenylalanine labelled milk protein or free amino acids with an identical constitution and \[1-13C\]-phenylalanine.

Main study endpoint will be the splanchnic extraction of phenylalanine, calculated from systemic \[1-13C\]- and L-\[ring2H5\]-phenylalanine enrichment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Incorporation of Dietary Protein-Derived Amino Acids in Duodenal Epithelium

NCT06091852

Protein Malabsorption

COMPLETED NA

Protein Consumption in Critically Ill Patients

NCT03048487

Critical Illness Dietary Modification

COMPLETED

Protein Dosing Strategies in Critically Ill Patients: Comparing Actual Body Weight and Fat-Free Mass Approaches in an Observational Cohort Study

NCT07312708

Critical Illness

RECRUITING

Hyperproteic Nutrition:Correlation of BUN to Nitrogen Balance

NCT00480259

Enteral Feeding

COMPLETED NA

Enhanced Protein Intake to Support Muscle Protein Synthesis in ICU

NCT06714240

Critical Illness Muscle Protein Synthetic Response to Protein

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Background of the study:

The importance of the provision of sufficient protein in critical illness is increasingly recognized. Protein malabsorption seems to be an underestimated but substantial problem in critically ill patients, limiting the amount of this important nutrient that actually becomes available within the systemic circulation. Among several contributors to malabsorption in critical illness, exocrine pancreatic insufficiency has recently emerged as a regularly occurring phenomenon during critical illness. Pancreatic insufficiency could lead to reduced digestion and subsequent uptake of enteral provided proteins. A proposed solution to this problem could be the use of elementary feeds containing free amino acids instead of whole protein. Due to the lack of easy applicable and reproducible tests for protein malabsorption the true efficacy of these feeds is still unknown. We hypothesize that enteral nutrition containing free amino acids leads to higher systemic levels of amino acids and will therefore increase the amount of dietary amino acids available for protein synthesis.

Objective of the study:

To quantitate the difference in digestion and absorption kinetics of dietary whole protein versus free amino acids in vivo in patients admitted to the ICU suffering from malabsorption.

Study design:

Randomized, single-blind controlled, single-centre, intervention study.

Study population:

16 adult, mechanically ventilated ICU patients with clinical signs of malabsorption (faecal weight \>350 g/day).

Intervention:

Normal enteral nutrition will be ceased 8 hours before the start of study participation. All patients will receive a primed continuous intravenous infusion of L-\[ring2H5\]-phenylalanine and L-\[3,5-2H2\]-Tyrosine for the duration of the study period. After reaching an isotopic steady state (1.5 hours), patients will receive either \[1-13C\]- phenylalanine labelled milk protein or free amino acids with an identical constitution and \[1-13C\]-phenylalanine.

Primary study parameters/outcome of the study:

Main study endpoint will be the splanchnic extraction of phenylalanine, calculated from systemic \[1-13C\]- and L-\[ring2H5\]-phenylalanine enrichment.

Secundary study parameters/outcome of the study:

Secondary endpoints include the impact of enteral nutrition on whole body protein balance, glucose and insulin concentrations and faecal energy and protein loss as a measure of malabsorption.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness:

Total study participation will take 16 hours, including 8 hours of fasting. Arterial blood samples will be collected regularly, with 50 ml of blood being sampled in total, amounting to a maximum of 1.0% of total circulating volume. All infusions, as well as blood sample collection, will be performed through indwelling catheters necessary for normal ICU treatment, meaning no lines or nasogastric tubes will have to be placed for the purposes of the study. Both isotopically labelled protein and free amino acids have been proven safe for use in humans and carry no harmful risks for the study participant. Changes in protein digestion, absorption and metabolism are specific to critical illness and their impact on the clinical condition and recovery of patients is severe. Investigating new strategies to modulate these effects are therefore essential, but require experimental studies in a vulnerable population. The risks in the present study are minimal whereas the results could help improve nutritional management in the intensive care.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Intestinal Malabsorption Critical Illness Protein Malnutrition

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Protein group

Patients receive 20 grams of Intrinsically labelled milk protein.

Group Type ACTIVE_COMPARATOR

Milk protein (food grade protein)

Intervention Type DIETARY_SUPPLEMENT

Subjects will receive an enteral nutritional formula containing 20 grams intrinsically labeled (1-\[13C\]-phenylalanine) milk protein

Free amino acid group

Patients receive 20 grams of free amino acids equivalent to the milk protein labelled with 13C-Phenylalanine

Group Type EXPERIMENTAL

Fee amino acids (food grade amino acids)

Intervention Type DIETARY_SUPPLEMENT

Nutritional formula containing 20 grams of a free amino acid mixture equivalent in composition to the milk protein with 1-\[13C\]-labeled phenylalanine

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Milk protein (food grade protein)

Subjects will receive an enteral nutritional formula containing 20 grams intrinsically labeled (1-\[13C\]-phenylalanine) milk protein

Intervention Type DIETARY_SUPPLEMENT

Fee amino acids (food grade amino acids)

Nutritional formula containing 20 grams of a free amino acid mixture equivalent in composition to the milk protein with 1-\[13C\]-labeled phenylalanine

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Protein Amino Acids

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age \> 18 and \< 75 years
2. Fecal weight \> 350g/day
3. Critical illness of any origin (e.g. medical, surgical, trauma) requiring admittance on ICU ward.
4. Expected ICU stay for the duration of the study protocol
5. Mechanically ventilated (PaO2/FiO2 ratio of \>100 and \<300)
6. Nasogastric tube in situ
7. Receiving full enteral nutrition without gastric residual volumes
8. Arterial (any location) line in situ
9. Flexi-seal system in situ

Exclusion Criteria

1. Proven (pre-existing) intestinal disease that potentially limits normal gut function and absorption of nutrients (e.g. IBD, short-bowel, entero-cutaneous fistulas including a surgical enterostomy)
2. Proven (pre-existing) primary pancreatic disease or obstruction of the pancreatic duct of any origin (e.g. pancreatitis, carcinoma).
3. Patients who are moribund (not expected to be in ICU for more than 48 hours due to imminent death)
4. A lack of commitment to full aggressive care during the first week due to severity of illness, comorbidities and potential harm from maximal treatment (anticipated withholding or withdrawing treatments)
5. Absolute contraindication to enteral nutrients (e.g., gastrointestinal \[GI\] perforation, obstruction or no GI tract access for any reason)
6. Receiving parenteral nutrition.
7. Nasoduodenal or nasojejunal feeding tube
8. Renal dysfunction defined as a serum creatinine \>171 umol/L or a urine output of less than 500 ml/last 24 hours
9. Patients requiring chronic veno-venous hemofiltration
10. Patients on ECMO/ELS
11. Cirrhosis - Child Pugh class C/D liver disease
12. Patients with primary admission diagnosis of burns (\>30% body surface area)
13. Weight less than 50 kg or greater than 100 kg
14. Pregnant patients or lactating with the intent to breastfeed
15. Previous randomization in this study
16. Enrolment in any other interventional study
17. Milk/lactose allergy
18. Previous participation in a 13C amino acid tracer study within the last year

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No